Teva (TEVA) CEO Departure Calls Strategy Into Question; Goldman Maintains Sell

October 30, 2013 10:38 AM

Goldman Sachs maintained a Sell rating on Teva Pharma (NYSE: TEVA) with a price target of $40.00. Analyst Jami Rubin ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found